~ Buy the BELSOMRA (suvorexant) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR BELSOMRA

All Clinical Trials for belsomra

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02491788 ↗	Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers	Completed	Merck Sharp & Dohme Corp.	Phase 4	2016-02-01	The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep.
NCT02491788 ↗	Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers	Completed	Stanford University	Phase 4	2016-02-01	The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep.
NCT02491788 ↗	Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers	Completed	VA Palo Alto Health Care System	Phase 4	2016-02-01	The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep.
NCT02527564 ↗	Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder	Recruiting	Merck Sharp & Dohme Corp.	Phase 4	2015-09-01	The purpose of this study is to evaluate the efficacy of suvorexant, added to existing medications, for treatment-resistant insomnia in individuals with bipolar disorder. The investigators hypothesize that participants receiving suvorexant for one week will experience significantly greater improvement in sleep duration compared to participants receiving placebo.
NCT02527564 ↗	Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder	Recruiting	Stanford University	Phase 4	2015-09-01	The purpose of this study is to evaluate the efficacy of suvorexant, added to existing medications, for treatment-resistant insomnia in individuals with bipolar disorder. The investigators hypothesize that participants receiving suvorexant for one week will experience significantly greater improvement in sleep duration compared to participants receiving placebo.

Clinical Trial Conditions for belsomra

Condition Name

Condition Name for belsomra
Intervention	Trials
Insomnia	16
Sleep Initiation and Maintenance Disorders	2
Postoperative Delirium	2
Bipolar Disorder	2

Condition MeSH

Condition MeSH for belsomra
Intervention	Trials
Sleep Initiation and Maintenance Disorders	20
Sleep Wake Disorders	7
Parasomnias	6
Disease	5

Clinical Trial Locations for belsomra

Trials by Country

Trials by Country for belsomra
Location	Trials
United States	30
Japan	1
Australia	1
Canada	1

Trials by US State

Trials by US State for belsomra
Location	Trials
California	5
Massachusetts	4
Michigan	4
Maryland	3
Washington	2

Clinical Trial Progress for belsomra

Clinical Trial Phase

Clinical Trial Phase for belsomra
Clinical Trial Phase	Trials
Phase 4	20
Phase 2/Phase 3	1
Phase 2	8

Clinical Trial Status

Clinical Trial Status for belsomra
Clinical Trial Phase	Trials
Recruiting	13
Completed	8
Not yet recruiting	6

Clinical Trial Sponsors for belsomra

Sponsor Name

Sponsor Name for belsomra
Sponsor	Trials
Merck Sharp & Dohme Corp.	8
Henry Ford Health System	3
Stanford University	3

Sponsor Type

Sponsor Type for belsomra
Sponsor	Trials
Other	41
Industry	12
NIH	5